Icon Plc (NASDAQ:ICLR) Shares Sold by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC reduced its stake in Icon Plc (NASDAQ:ICLR) by 1.3% during the second quarter, Holdings Channel reports. The institutional investor owned 11,015 shares of the medical research company’s stock after selling 144 shares during the period. Janney Montgomery Scott LLC’s holdings in Icon Plc were worth $1,077,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Harbour Capital Advisors LLC boosted its position in Icon Plc by 9,679.1% in the second quarter. Harbour Capital Advisors LLC now owns 41,561 shares of the medical research company’s stock valued at $425,000 after buying an additional 41,136 shares in the last quarter. NGAM Advisors L.P. boosted its position in Icon Plc by 0.9% in the second quarter. NGAM Advisors L.P. now owns 86,009 shares of the medical research company’s stock valued at $8,411,000 after buying an additional 762 shares in the last quarter. Reliance Trust Co. of Delaware acquired a new position in Icon Plc during the second quarter valued at $1,175,000. Russell Investments Group Ltd. boosted its position in Icon Plc by 3.9% in the second quarter. Russell Investments Group Ltd. now owns 141,316 shares of the medical research company’s stock valued at $13,820,000 after buying an additional 5,325 shares in the last quarter. Finally, Huntington National Bank boosted its position in Icon Plc by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after buying an additional 77 shares in the last quarter. 92.55% of the stock is currently owned by institutional investors and hedge funds.
Icon Plc (ICLR) opened at 101.40 on Friday. The stock’s 50 day moving average price is $100.50 and its 200-day moving average price is $89.05. The stock has a market cap of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60. Icon Plc has a 12 month low of $73.76 and a 12 month high of $109.32.
Icon Plc (NASDAQ:ICLR) last released its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. The company had revenue of $431 million for the quarter, compared to the consensus estimate of $430.68 million. Icon Plc had a return on equity of 26.34% and a net margin of 15.04%. Icon Plc’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 earnings per share. Analysts anticipate that Icon Plc will post $5.32 EPS for the current fiscal year.
Several research analysts have weighed in on the company. KeyCorp reissued an “overweight” rating on shares of Icon Plc in a research report on Monday, July 31st. SunTrust Banks, Inc. raised Icon Plc from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $93.00 to $126.00 in a research report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating on shares of Icon Plc in a research report on Sunday, July 30th. Credit Suisse Group reissued a “buy” rating on shares of Icon Plc in a research report on Friday, July 28th. Finally, Mizuho boosted their price objective on Icon Plc from $104.00 to $108.00 and gave the stock a “neutral” rating in a research report on Thursday, July 27th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $108.38.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.